Dr Alex Matter is no stranger oncology experts. Formerly the Global Head of Oncology Research at Novartis, he also played an important role in the success of several anticancer drugs, including Gleevec/Glivec® and more recently, Tasigna® and several other anticancer drugs as well as one HIV protease inhibitor (Reyataz®) that is marketed by another company. Ahead of Dr Matter joining us …
